Built: all 18 canonical wiki pages; bibliography; 6 landmark notes; guideline registry; statistics; patient-voice method, themes and sources; tiered open questions with a Dots table.
Live searches: 38 PubMed E-utilities topic searches plus a batch EFetch resolving 281/287 candidate PMIDs; ClinicalTrials.gov v2 searches for neuropathic pain, painful diabetic neuropathy, CIPN, PHN and SCI neuropathic pain.
Trial snapshot: live registry statuses and NCT identifiers were used only on the trials page.
Integration: INDEX updated with reading paths and literature artifacts; roadmap status set to built.
Patient organizations: live websites verified for six organizations spanning the US/international, Europe, UK and Australia; geographic/language gaps remain explicit.
Next: run the playbook’s required independent audit session; re-fetch every cited PMID/NCT, check claim-to-record fit and quantitative transcription, and promote only passing pages to curated.
Scope: extended—not replaced—all 18 canonical wiki pages. Final page lengths are 171–206 lines; every page now carries 28–34 unique PMID references, retains status: draft, and has last-curated: 2026-08-30.
Foundation pages: added screening-instrument performance and limitations (LANSS, S-LANSS, DN4 and painDETECT), updated SCI prevalence, channelopathy/genotype evidence, Schwann-cell bioenergetics, sodium-channel translation limits, phase-dependent microglial biology, complement-mediated disinhibition, and clearer QST inference boundaries.
Etiology and safety pages: added quantified painful-diabetic-neuropathy burden; PHN vaccine effectiveness and postsurgical risk/prevention estimates; CIPN exercise, cooling/compression and fall-risk evidence; central-pain lesion/topography and rehabilitation data; patient-reported outcome instruments and qualitative evidence; and diagnostic-accuracy plus medication-withdrawal/interaction safety evidence.
Treatment and frontier pages: added head-to-head and combination pharmacotherapy trials, capsaicin and botulinum-toxin trials, DRG/SCS randomized and durability data, biomarker and phenotype-stratified trials, expanded cross-national guideline disagreements, minimum-important-difference controls, and a current 16-record trial-status table.
Shared literature: expanded BIBLIOGRAPHY.md to 305 unique PMIDs; expanded STATISTICS.md with confidence intervals and conditional-denominator caveats for diabetes, SCI, zoster vaccination, trigeminal neuralgia, stroke, MS, amputation, burns and CIPN falls; expanded REGISTRY.md beyond 25 documents/consensuses with methods, supersession and disagreement notes; sharpened OPEN-QUESTIONS.md from 18 to 22 stable questions and added a minimum-decisive-design table for every question.
Live searches: PubMed E-utilities searches covered definition/grading, diagnostic instruments, population burden, channelopathies and Schwann cells, neuroimmune plasticity, QST/phenotyping, each major etiology, patient-reported outcomes, red flags and drug harms, pharmacologic comparisons/combinations, topical and implanted treatments, biomarkers, trial methods, and international/national guidance. ClinicalTrials.gov v2 was queried for every NCT identifier retained on the trials page.
Identifier closure: a final whole-condition live sweep resolved 305/305 unique PMIDs through PubMed E-utilities and 16/16 unique NCT IDs through ClinicalTrials.gov v2. Local checks found no wiki PMID absent from the bibliography, no inline PMID absent from its page reference section, no duplicate bibliography PMID, no malformed heading artifact and no unresolved verification flag.
Interpretive choice: guidance-like documents are labeled by method—formal guideline, systematic-review-based recommendation or expert/Delphi consensus—rather than pooled as equivalent authority; conflicting prevalence estimates remain side by side rather than averaged.
Next: conduct the playbook’s required independent audit in a separate session, checking every claim-number-to-source match and every trial-status snapshot before considering any page for curated promotion. Update-watch priorities are NeuPSIG pharmacotherapy/interventions, ASCO CIPN, CanPainSCI, and national documents whose English summaries or evidence searches are aging.
Scope checked: all 18 canonical wiki pages and all 13 Markdown artifacts under literature/ (309-entry bibliography, 6 landmark notes, guideline registry, statistics, and 4 patient-voice files).
Citation closure: checked 508 body claim-to-PMID occurrences and 550 page-to-PMID reference pairs. A fresh live PubMed E-utilities ESummary/EFetch sweep resolved 309/309 unique PMIDs; inline first-author/year checks produced 0 residual mismatches. The 16/16 unique NCT identifiers were re-fetched individually from the ClinicalTrials.gov v2 API, including current status, enrollment, completion date, condition and intervention fields.
Quantitative review: rechecked reported sample sizes, prevalence estimates, confidence intervals, NNTs, responder proportions, hazards and trial outcomes against live abstracts/records. No quoted effect size required numerical correction; conditional denominators and nonrandomized inference limits were retained or strengthened.
Citation errors fixed: corrected 17 pre-existing metadata defects—11 wrong journal/volume/page/title records on peripheral-mechanisms.md, 3 on epidemiology-and-burden.md, the missing German title in both biomarkers.md and BIBLIOGRAPHY.md, and the incorrect DOI in the SENZA-PDN landmark note. Also repaired 3 bibliography cited by omissions.
Stale-absence searches: reran targeted PubMed searches for diagnostic/treatment-predictive biomarkers, phenotype-by-treatment interactions, painful-diabetic-neuropathy disease modification, SCS ulcer/amputation/regeneration outcomes, current CIPN prevention, sex-specific treatment algorithms, human DRG-macrophage markers and clinical tests of peripheral-input dependence. Re-queried ClinicalTrials.gov for the phenotype-stratified SPENDD strategy.
Evidence-gap corrections: replaced 8 overbroad or potentially stale absence statements across 7 pages with dated positive evidence-gap formulations. Added live-verified records for a 2026 RNA-biomarker review (PMID 42534835), the PROSPER phase III CIPN-prevention protocol (PMID 42583153), human DRG macrophage localization (PMID 38691673), and a 2025 observational SCS/amputation analysis (PMID 41079020). The SCS page now reports the observational amputation association while explicitly withholding a causal prevention claim.
Non-journal sources: rechecked NICE CG173 and six patient-organization URLs on 2026-08-30. Four official sites resolved directly; three rejected or timed out direct automated requests but were confirmed through current search-engine crawls of the same official domains. This is an access-method limitation, not an unresolved organization identity or scope issue.
Outcome: all 18 pages passed and were promoted to status: curated; INDEX.md and CONDITIONS-ROADMAP.md now show audited. Remaining substantive citation flags: 0. Remaining verification flags: 0. Update watch remains appropriate for completed SPENDD/PROSPER results, a post-OPTION-DM NeuPSIG pharmacotherapy update, and prospective ulcer/amputation endpoints in SCS studies.